478 related articles for article (PubMed ID: 26456076)
21. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
23. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
Das DS; Das A; Ray A; Song Y; Samur MK; Munshi NC; Chauhan D; Anderson KC
Clin Cancer Res; 2017 Aug; 23(15):4280-4289. PubMed ID: 28270494
[No Abstract] [Full Text] [Related]
24. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
25. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
26. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
27. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
28. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
Boccellato C; Kolbe E; Peters N; Juric V; Fullstone G; Verreault M; Idbaih A; Lamfers MLM; Murphy BM; Rehm M
Cell Death Dis; 2021 Jun; 12(7):647. PubMed ID: 34168123
[TBL] [Abstract][Full Text] [Related]
29. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
30. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
31. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
32. Pomalidomide for the management of refractory multiple myeloma.
Summers BB; Cole SW; Olin JL
Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
[TBL] [Abstract][Full Text] [Related]
33. Novel generation of agents with proven clinical activity in multiple myeloma.
Mateos MV; Ocio EM; San Miguel JF
Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
[TBL] [Abstract][Full Text] [Related]
34. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.
Song Y; Ray A; Li S; Das DS; Tai YT; Carrasco RD; Chauhan D; Anderson KC
Leukemia; 2016 Sep; 30(9):1877-86. PubMed ID: 27118409
[TBL] [Abstract][Full Text] [Related]
35. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
[TBL] [Abstract][Full Text] [Related]
36. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG; Schlossman RL; Weller E; Hideshima T; Mitsiades C; Davies F; LeBlanc R; Catley LP; Doss D; Kelly K; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo JJ; Chauhan D; Balinski K; Zeldis J; Anderson KC
Blood; 2002 Nov; 100(9):3063-7. PubMed ID: 12384400
[TBL] [Abstract][Full Text] [Related]
38. Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in
Borsi E; Martello M; Santacroce B; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Cavo M; Terragna C
Haematologica; 2018 Dec; 103(12):e602-e606. PubMed ID: 30026343
[No Abstract] [Full Text] [Related]
39. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Hoy SM
Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
[TBL] [Abstract][Full Text] [Related]
40. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]